Clinical Trials Results - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -8 of 8 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Phase II Study of CI-958 for Metastatic or Locally Recurrent Colorectal Carcinoma (Summary last Modified 07/96)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				WSU-C-1287 NCI-T96-0003H, T96-0003

Last Modified: 6/1/1998


2.		Phase II Study of CI-958 (a Benzothiopyranoindazole DNA Intercalator) for Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum (Summary Last Modified 06/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				MDA-DM-96101 NCI-T96-0034D, T96-0034

Last Modified: 5/1/1998


3.		Phase II Study of CI-958 for Refractory or Recurrent Ovarian Cancer (Summary Last Modified 05/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				UCCRC-8233 NCI-T96-0039H, T96-0039

Last Modified: 10/1/1999


4.		Phase II Study of CI-958 in Hormone Refractory Metastatic Prostate Carcinoma (Summary Last Modified 10/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				OSU-9617 CWRU-1897, OSU-T96-0054, NCI-T96-0054D, T96-0054

Last Modified: 4/1/2002


5.		Phase II Study of CI-958 in Recurrent Platinum-Sensitive Ovarian Cancer and Primary Peritoneal Carcinoma (Summary Last Modified 04/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Not specified				NCI				GOG-146E

Last Modified: 1/1/1998


6.		Phase II Open Label Study of CI-958 in Patients with Metastatic Breast Cancer (Summary Last Modified 01/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				PD-958-05 NCI-V97-1208

Last Modified: 11/1/2000 First Published: 11/1/2000


7.		Phase II Study of CI-958 in Patients With Recurrent, Platinum-Resistant, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Carcinoma (Summary Last Modified 11/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Adult				NCI				GOG-126G

Last Modified: 5/2/2007


8.		Phase I Study of CI-958 (a Synthetic Intercalating Agent) for Recurrent Pediatric Solid Tumors and Lymphomas (Summary Last Modified 05/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				21 and under				NCI				CCG-0943 CCG-0943

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute